1-{2-[2,2-bis(4-fluorophenyl)(hydroxy)acetoxy]ethyl}-3-(cyclopropylmethyl)-2-methyl-1H-imidazol-3-ium bromide | 1051920-93-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 1-{2-[2,2-bis(4-fluorophenyl)(hydroxy)acetoxy]ethyl}-3-(cyclopropylmethyl)-2-methyl-1H-imidazol-3-ium bromide
• 英文别名: 2-[3-(Cyclopropylmethyl)-2-methylimidazol-3-ium-1-yl]ethyl 2,2-bis(4-fluorophenyl)-2-hydroxyacetate;bromide
• CAS: 1051920-93-4
• 化学式: Br*C₂₄H₂₅F₂N₂O₃
• 分子量: 507.375
• InChiKey: QKXWBWGQKZVWFW-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  0.26
• 重原子数：
  32
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  55.3
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• MUSCARINIC RECEPTOR ANTAGONISTS
  申请人：Kumar Naresh

  公开号：US20100168197A1

  公开（公告）日：2010-07-01

  This present invention generally relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors.

  这项发明通常涉及肌肉型受体拮抗剂，这些拮抗剂可用于治疗通过肌肉型受体介导的呼吸系统、泌尿系统和消化系统的各种疾病，此外，该发明还涉及所述化合物的制备过程、含有所述化合物的制药组合物以及治疗通过肌肉型受体介导的疾病的方法。
• Compositions of phosphodiesterase type IV inhibitors
  申请人：Ranbaxy Laboratories Limited

  公开号：EP2111861A1

  公开（公告）日：2009-10-28

  Provided herein are pharmaceutical compositions comprising one or more phosphodiesterase inhibitors of type IV ("PDE-IV"), and atleast one other active ingredients selected from muscarinic receptor antagonists (MRA), β2-agonists, p38 MAP Kinase inhibitors, and corticosteroids and optionally one or more pharmaceutically acceptable excipients and/or other therapeutic agents. In addition, methods of treating autoimmune, inflammatory or allergic diseases or disorders are provided.

  本文提供的药物组合物包含一种或多种IV型磷酸二酯酶抑制剂（"PDE-IV"）、至少一种选自毒蕈碱受体拮抗剂（MRA）、β2-激动剂、p38 MAP激酶抑制剂和皮质类固醇的其他活性成分，以及可选的一种或多种药学上可接受的赋形剂和/或其他治疗剂。此外，还提供了治疗自身免疫性、炎症性或过敏性疾病或紊乱的方法。
• COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS
  申请人：Ray Abhijit

  公开号：US20100004215A1

  公开（公告）日：2010-01-07

  Provided herein are pharmaceutical compositions comprising one or more phosphodiesterase inhibitors of type IV (“PDE-IV”), and at least one other active ingredient such as muscarinic receptor antagonists (MRA), β2-agonists, p38 MAP Kinase inhibitors, or corticosteroids and optionally one or more pharmaceutically acceptable excipients. In addition, methods of treating autoimmune, inflammatory or allergic diseases or disorders are provided.
• [EN] MUSCARINIC RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS MUSCARINIQUES
  申请人：RANBAXY LAB LTD

  公开号：WO2008104942A2

  公开（公告）日：2008-09-04

  [EN] This present invention generally relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors.
  [FR] L'invention porte sur des antagonistes des récepteurs muscariniques, notamment utiles pour traiter différentes maladies des systèmes respiratoire, urinaire et gastro-intestinal, médiées par les récepteurs muscariniques. L'invention porte également: sur le procédé de préparation desdits composés; sur des préparations pharmaceutiques les comprenant, et sur des méthodes de traitement de maladies médiées par les récepteurs muscariniques.